Review on Liposome as Novel Approach for Cancer Therapy
DOI:
https://doi.org/10.22270/ajprd.v8i3.724Keywords:
Liposome, Targeted drug delivery system, controlled drug delivery, Immunotherapy.Abstract
The main objective is to study the importance of liposome in drug targeting in cancer cells andgo through various research work going through on liposome. The importance of liposomes to study the flexibility to couple with the specific ligands toachieve active targeting. Cancer can be treated by surgery, radiation, chemotherapy, gene therapy, immunotherapy, hormone therapy. Cancer is the uncontrolled growth of abnormal cell anywhere in a body. The abnormal cells aretermed cancer cells, malignant cells, or tumor cells. There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2018 worldwide. 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.
Downloads
References
2. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002267 /(accessed date 20.9.19)
3. http://www.medicinenet.com/cancer/page4.htm#types (accessed date 21.9.19
4. Tripathi KD; Essential of Medical Pharmacology; 6th & 7th edition; jaypee brothers medical publishers New Delhi; 2008 2010; Pp 820.
5. Vyas S.P. et al; Targeted & Controlled drug delivery novel carrier system; 1st edition; CBS publication New Delhi; 2000; Pp 38-42, 173,174,181,196,217,224
6. NillBergstrand; Liposomes for Drug Delivery from Physico-chemical Studies to Applications 2003.
7. Elenaz n; investigation and optimization of liposome formulation for use as drug carrier for the anticancer agent camptothecin; 2013-14.
8. Mohammad riaz; liposomes preparation methods; vol.19(1), january 1996, pp.65-77
9. Weissia V; Liposomes Method and Protocols; volume 1 Pharmaceutical nanocarrier; Humana press; 2010; Pp 3
10. Tardi Paul et al; Liposomal Encapsulation of Topotecan and investigated its Anticancer Efficacy in Murine and Human Xenograft Models; American Association for Cancer Research 2010; Pp 60; 3389
11. Zamboni W.C; Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents;Clin Cancer Res December 1, 2005 11; 8230
12. Maitani Y et al; Artificial lipids stabilized camptothecin incorporated in liposome; Biol Pharm Bull. 2008 May; 31(5):990-3.
13. Sun D.S et al; Treatment of hepatoma with liposome-encapsulated Adriamycin administered into hepatic artery of rats; World J Gastroenterol. 2006; 12(29):4741-4
14. Sonq S. et al; Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo; FASEB J. 2009; 23(5):1396-404
15. Qi X et al; Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein; Clin Cancer Res. 2009; 15(18):5840-51
16. Zhenq H et al; Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo; PLoS One. 2011; 6(6):e21064
17. Antonio P.D. et al; Liposomes encapsulating anticancer drugs and use thereot in the treatment of malignant tumors; 2006; US Patent Application; 20050100590.
18. Janoff A.S. et al; liposomal defensis; 1998; US Patent 5766624
19. Eric M. et al; Etherlipid- containing multiple lipid liposomes, 2006; Patent RE 39042
20. Larsen h. et al; radioactive therapeutic liposomes; 2006; Patent 65928+3
21. Noburo Y. et al; Sugar- modified liposome and products comprising the liposomes; 2006; US Patent Application 20060110798.
22. Drummond D.C. et al; examined liposomes useful for drug delivery to the brain; 2007; US Patent Application 20070110798.
23. Madden T. et al; Liposomal camptothecins and uses thereof; 2006; Patent 7060828.
24. Xie Y et al; Drug delivery to the lymphatic system; importance in future cancer diagnosis and therapies; 2009; 6(8):785- 792.
25. Sawant R.R. et al; Palmitoyl Ascorbate liposomes and free ascorbic Acid; comparison of Anticancer therapeutic effects Upon parenteral Administration; 20011; 21845505
26. Mitrus I et al; combination of combretastastation A4 phosphate and doxorubicin- containing liposomes affects growth of B16 – F10 tumors; 2009; 9287800.
27. Pei Kan P et al; A Liposomal formulation Able to Incorporate a High content of Paclitaxel and Exert Promising Anticancer effect; 2010; 629234.
28. Hwang T. et al; Anticancer Drug- Phospholipid conjugate for Enhancement of Intracellular Drugs Delivery; Macromal Symp. 2007 April; 249-250(1); 109-115.
29. Zhou R. et al; Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model; J Pharmacol Exp Ther. 2010; 332 (2); 479-488.
30. Chen H. et al; Folate- Mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide; Mol Cancer Ther 2009; 8(7):1955-1963.
31. Verreault M. et al; Vascular Normalization in orthotopic glioblastoma following intravenous treatment with lipid- based nanoparticulate formulations of irinotecan (IrinophoreCTm),Doxorubicin (Caelyx) or vincristine; 2011 April 8 10. 1186/1471-11-124.
32. Marije Slingerland et al; “Drug discovery today” Volume 17 Number 4 Feb. 2012.
33. Fanciullino R. and Ciccolini J. et al; “Current medicinal chemistry” Volume-33, ISSN- 1875-5337, 2013
34. Savia Calderia et al; “Liposome as carriers of Anticancer drug” ISBN-978-953-51-1098-9; May 2013.
35. MarileneEstanqueiro et al; “International Journal of current Pharmaceutical Research”Volume-6, Issue-4 Oct.-Dec.-2014.
36. Tianyue Jiang et al; “Advances functional material” Volume-24, Issue-16, pp- 2295-2304; April 2014.
37. Andreas hochhaus et al; “Anticancer drug” 16(7); 691-707, March 2014.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.